Pfizer (PFE) Receives European Approval for ZIRABEV, Biosimilar to Avastin

February 19, 2019 9:33 AM
Pfizer Inc. (NYSE: PFE) today announced the European Commission (EC) has approved ZIRABEV™ for the treatment of metastatic carcinoma of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles